Compare Neurocrine Biosciences Inc (NBIX) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Snap On Incorporated — how do they compare? Neurocrine Biosciences Inc trades at $142.45 (market cap $14.36B), while Snap On Incorporated trades at $360.49 (market cap $18.56B). The key difference: Snap On Incorporated is the larger of the two by market cap, and Snap On Incorporated pays a 2.72% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Snap On Incorporated for 36 Days on average.
| NBIX | SNA | |
|---|---|---|
Market Cap | $14.36B | $18.56B |
Volume | 1,237,180 | 401,326 |
Sector | Health | Industrials |
52-Week High | $185.50 | $419.31 |
52-Week Low | $123.10 | $327.33 |
Typical Hold Time | 23 Days | 36 Days |
Enterprise Value | $14.37B | $18.20B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Snap-On Incorporated (SNA) trades at $359.89, down 2.37% on the day, with technical indicators showing bearish momentum despite strong fundamentals. The company maintains robust profitability with 19.6% net margins and 17.58% ROE, supported by consistent earnings beats in recent quarters. Analyst consensus remains bullish with a $449 price target, representing 25% upside potential from current levels.
SNA offers attractive fundamentals with expanding gross margins and solid cash flow generation, though technical weakness and premium valuation present near-term headwinds. The stock's investment case hinges on continued execution of RCI initiatives and diagnostic segment growth, balanced against valuation concerns and mixed technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
